Phase II trial of vinorelbine and estramustine in the treatment of metastatic hormone-resistant prostate cancer
- 29 February 2004
- journal article
- clinical trial
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 22 (1) , 32-35
- https://doi.org/10.1016/s1078-1439(03)00102-9
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- The Treatment Challenge of Hormone-Refractory Prostate CancerCancer Control, 2001
- Vinorelbine and estramustine in androgen-independent metastatic prostate cancerCancer, 2000
- Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: A phase II trialAnnals of Oncology, 1999
- Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working GroupJournal of Clinical Oncology, 1999
- Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III TrialJournal of Clinical Oncology, 1999
- Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer.Journal of Clinical Oncology, 1997
- Estramustine Phosphate SodiumDrugs & Aging, 1995
- Inhibition of prostate cancer growth by vinblastine and tamoxifenThe Prostate, 1995
- Androgen Suppression by Hydrocortisone without Aminoglutethimide in Orchiectomised Men with Prostatic CancerBritish Journal of Urology, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958